Advertisement
Research Article

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

  • Bambang S. Adiwijaya mail,

    bambang_adiwijaya@vrtx.com

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Eva Herrmann,

    Affiliation: Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

    X
  • Brian Hare,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Tara Kieffer,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Chao Lin,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Ann D. Kwong,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Varun Garg,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • John C. R. Randle,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Christoph Sarrazin,

    Affiliation: Medizinische Klinik 1, J. W. Goethe-University Hospital, Frankfurt am Main, Germany

    X
  • Stefan Zeuzem,

    Affiliation: Medizinische Klinik 1, J. W. Goethe-University Hospital, Frankfurt am Main, Germany

    X
  • Paul R. Caron

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Published: April 15, 2010
  • DOI: 10.1371/journal.pcbi.1000745

About the Authors

Bambang S. Adiwijaya, Brian Hare, Tara Kieffer, Chao Lin, Ann D. Kwong, Varun Garg, John C. R. Randle, Paul R. Caron
Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America
Eva Herrmann
Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
Christoph Sarrazin, Stefan Zeuzem
Medizinische Klinik 1, J. W. Goethe-University Hospital, Frankfurt am Main, Germany

Corresponding Author

Email: bambang_adiwijaya@vrtx.com

Competing Interests

BSA, BH, TK, CL, ADK, VG, PRC are employed by Vertex Pharmaceuticals, Incorporated. JCRR was previously employed by Vertex Pharmaceuticals, Incorporated. EH, CS and SZ have received funding from Vertex Pharmaceuticals, Incorporated for other projects. Vertex Pharmaceuticals, Incorporated is the manufacturer of telaprevir.

Author Contributions

Conceived and designed the experiments: TK ADK VG JCRR CS SZ. Performed the experiments: TK CL CS SZ. Analyzed the data: BSA EH BH TK ADK VG JCRR CS SZ PRC. Contributed reagents/materials/analysis tools: BSA. Wrote the paper: BSA EH BH TK ADK VG JCRR SZ PRC.